16:30 EST Emergent BioSolutions (EBS) sees Q1 revenue $200M-$240M, consensus $279M
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions reports Q4 adjusted EPS 5c, consensus (50c)
- Emergent BioSolutions sees FY25 revenue $750M-$850M, consensus $1.13B
- Mpox strain with higher transmission rate detected in Congo, Bloomberg reports
- Is EBS a Buy, Before Earnings?
- Emergent BioSolutions, Smith raise awareness on opioid poisonings